Abstract
IntroductionMany children with juvenile idiopathic arthritis (JIA) continue to have active disease into adulthood. Adults with JIA are a heterogeneous group, and the effects of tumour necrosis factor inhibitor (TNFi) therapies are not well described. This analysis aims to describe treatment outcomes among patients with JIA starting TNFi for the first time in adulthood.MethodsPatients with arthritis onset <16 years starting their first TNFi therapy were identified from the British Society of Rheumatology Biologics Register. Disease activity outcomes (using 28-joint Disease Activity Score (DAS28) and Health Assessment Questionnaire (HAQ)) are presented at 1 year after start of therapy according to disease pattern. Incidence rates (IR) of adverse events per 1000 person-years (pyrs) were calculated. Outcomes in patients with polyarticular JIA were compared with a cohort (weighted for age and gender) of patients with rheumatoid arthritis (RA).ResultsIn 443 adults with JIA starting a first TNFi, disease activity over 1 year improved across all measures. There were 58 first serious infections (IR 22.3/1000 pyrs); 4 cardiovascular events (IR 1.4/1000 pyrs); 11 uveitis events (IR 4.0/1000 pyrs) and 16 malignancies (IR 3.9/1000 pyrs). Compared with the weighted RA cohort, disease activity improvement was similar; malignancy rates were lower and uveitis rates much higher. While crude IR were similar, JIA patients had a lower risk of serious infection (HR 0.5 (95% CI 0.3 to 0.9)).ConclusionsThis is the largest study to describe disease activity and safety outcomes in adults with JIA receiving TNFi. Disease activity improved after 1 year in all disease patterns, suggesting TNFi is an effective therapy in this population.
Highlights
Many children with juvenile idiopathic arthritis ( Juvenile idiopathic arthritis (JIA)) continue to have active disease into adulthood
▸ This study shows that tumour necrosis factor inhibitor (TNFi) are an effective therapeutic option for adults with JIA, with a safety profile similar to that seen in rheumatoid arthritis
92 (21%) were listed as having JIA within the BSRBR-rheumatoid arthritis (RA) data set, the remainder were listed as having an adult diagnosis
Summary
Many children with juvenile idiopathic arthritis ( JIA) continue to have active disease into adulthood. Adults with JIA are a heterogeneous group, and the effects of tumour necrosis factor inhibitor (TNFi) therapies are not well described This analysis aims to describe treatment outcomes among patients with JIA starting TNFi for the first time in adulthood. ▸ Tumour necrosis factor inhibitors (TNFi) have been shown to be an effective treatment for children with juvenile idiopathic arthritis ( JIA) when started in childhood. ▸ This study shows that TNFi are an effective therapeutic option for adults with JIA, with a safety profile similar to that seen in rheumatoid arthritis How might this impact on clinical practice?. First-line treatment with methotrexate, including a trial of subcutaneous methotrexate, is recommended for children with more severe forms of arthritis with the addition of tumour necrosis factor inhibitors (TNFi) for non-responders or those who are intolerant. Aggressive approach with the goal of early remission. In the UK, the current evidence base (including clinical trials and observational data) has enabled the development of treatment guidelines for children with JIA. In particular, first-line treatment with methotrexate, including a trial of subcutaneous methotrexate, is recommended for children with more severe forms of arthritis with the addition of tumour necrosis factor inhibitors (TNFi) for non-responders or those who are intolerant.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
